S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Is Gold Really Boring? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Critical asset just had biggest fall on record (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales

Fusion Pharmaceuticals (FUSN) Earnings Date, Estimates & Call Transcripts

$12.50
-0.15 (-1.19%)
(As of 02/27/2024 ET)
Skip Charts & View Estimated and Actual Earnings Data

FUSN Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

FUSN Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Fusion Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20245($0.40)($0.19)($0.34)
Q2 20245($0.44)($0.20)($0.36)
Q3 20245($0.44)($0.21)($0.35)
Q4 20245($0.45)($0.22)($0.37)
FY 202420($1.73)($0.82)($1.42)

FUSN Earnings Date and Information

Fusion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 21st, 2024 based off prior year's report dates.

Fusion Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
3/21/2024
Estimated)
------- 
11/7/2023Q3 2023($0.40)($0.25)+$0.15($0.25)$0.41 million$2.01 million
8/8/2023Q2 2023($0.39)($0.38)+$0.01($0.38)$0.30 million$0.03 million
5/11/2023Q1 2023($0.29)($0.45)($0.16)($0.45)-$0.03 million
3/16/2023Q4 2022($0.57)($0.55)+$0.02($0.55)$0.12 million$0.14 million
11/8/2022Q3 2022($0.52)($0.55)($0.03)($0.55)$0.50 million$0.17 million
8/9/2022Q2 2022($0.53)($0.44)+$0.09($0.44)$0.55 million$0.57 million
5/10/2022Q1 2022($0.50)($0.46)+$0.04($0.46)$4.50 million$0.59 million
3/17/2022Q4 2021($0.47)($0.40)+$0.07($0.40)-$0.59 million
11/9/2021Q3 2021($0.58)($0.45)+$0.13($0.45)-$0.33 million
8/10/2021Q2 2021($0.39)($0.63)($0.24)($0.63)-$0.52 million
5/11/2021Q1 2021($0.28)($0.42)($0.14)($0.42)--
3/24/2021Q4 2020($0.19)($0.32)($0.13)($0.32)--












Fusion Pharmaceuticals Earnings - Frequently Asked Questions

When is Fusion Pharmaceuticals's earnings date?

Fusion Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 21st, 2024 based off last year's report dates. Learn more on FUSN's earnings history.

How much revenue does Fusion Pharmaceuticals generate each year?

Fusion Pharmaceuticals (NASDAQ:FUSN) has a recorded annual revenue of $1.46 million.

How much profit does Fusion Pharmaceuticals generate each year?

Fusion Pharmaceuticals (NASDAQ:FUSN) has a recorded net income of -$87.61 million. FUSN has generated -$1.63 earnings per share over the last four quarters.

What is Fusion Pharmaceuticals's EPS forecast for next year?

Fusion Pharmaceuticals's earnings are expected to grow from ($1.44) per share to ($1.39) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:FUSN) was last updated on 2/28/2024 by MarketBeat.com Staff